All Pages

• eviCHO Expression Kit

• Opti-mAb® scFv Stabilization

• Government-funded research institutions

• Acadamic research institutions

• Recommended downloads

• Solutions

• Integral Molecular

• Publications

• Encyclopedia

• Recombinant Protein Expression Service

• Bispecific Antibody Production Service

• Fc-Silenced Antibody Expression Service

• Afucosylated Antibody Expression Service

• Recombinant Antibody Expression Service

• ProBioGen

• Rapid Novor

• Lonza

• Atlas Antibodies

• Partnerships

• Transient Antibody Production

• Scalability & Reproducibility

• Antibody reformatting and engineering

• CHO cells – first choice for antibody production

• Antibody journal

• Newsletter

• LinkedIn Journal Club

• Therapeutics development

• About Evitria

• Events

• FAQs

• Contact

• Privacy Policy

• HTML Sitemap

• Welcome to evitria

All Posts

• Antibody-Dependent Cellular Cytotoxicity (ADCC) – Definition, Mechanism & Application

• Afucosylated recombinant antibodies

• Recombinant Antibodies – 7 key insights to rAbs

• High-Throughput Antibody Production: A Guide to Workflows, Platforms, and Decision-Ready Data

• What is the Typical Turnaround Time for HTP Antibody Production?

• Developability-by-Design: The 5 Readouts to Check Before Picking Winners

• Why HTP Screening Results Sometimes Fail to Translate to Manufacturing

• High-Throughput Screening (HTS): Moving from Production to Data

• Benefits of High-Throughput Antibody Expression in Early-Stage Discovery

• The Top 5 Problems with High-Throughput Antibody Expression and How to Avoid Them

• How to Design an HTP Screening Campaign for Reliable Lead Comparability

• Primary vs. Secondary Screening: Why CHO-Based Material is Essential

• Hidden Costs in HTP: Why “Cheap” HEK293 Material Costs Millions Later

• Batch Effects in HTP: Identifying Sources and Strategies for Reduction

• Transient vs. Stable Expression in HTP: When to Make the Switch

• Recombinant protein: definition, examples & production

• Recombinant Protein Expression in Mammalian Cells: Techniques and Applications

• Recombinant antibody expression – the process in detail

• Recombinant Antibody Production: Complete Guide

• Garbage In, Garbage Out: Why AI Antibody Discovery Needs Data Integrity

• HTP vs. Preclinical-Scale Antibody Production: When Should You Scale Up?

• How Automation in HTP Antibody Production Reduces Batch Variation in CHO Expression

• AAX Biotech and evitria to expand access to Opti-mAb® technology in early antibody development 

• HEK293 vs. CHO for HTP Antibody Expression: Impact on Glycosylation and Folding

• Transient vs. Stable Expression in High-Throughput Antibody Screening: When to Switch

• Physical Validation at Scale: How HTP Supports AI-Designed Antibody Discovery

• Fail Fast, Succeed Faster: The Role of Early Developability Assessment

• Recombinant DNA technology – Steps, Methods & Examples

• Recombinant antibody purification – methods, steps and challenges

• Bispecific antibody companies: What companies are developing bispecific drug products?

• Polyclonal Antibody Production: A Comprehensive Guide

• Bispecific Antibody Formats – exploring the diverse types & formats in therapeutic development

• Monoclonal antibody production: Process, Technologies & Steps

• Understanding recombinant protein production: from discovery to developability

• FDA approved bispecific antibodies

• Bispecific Antibodies: A Comprehensive Overview

• Advantages and Disadvantages of Recombinant DNA Technology

• Understanding the side effects of bispecific antibodies

• Applications of recombinant proteins

• Application of recombinant DNA technology: What is rDNA used for?

• Differences between monoclonal antibodies and recombinant monoclonal antibodies

• What are examples of bispecific drugs?

• What is the difference between a monoclonal and a bispecific antibody?

• Speed vs. Quality in Early Drug Development: Striking the Right Balance for Antibody Therapeutics

• Why Promising Antibody Candidates Fail Before Clinical Trials – and How to Avoid It

• Fast-Tracking Bispecific Antibody Development: What Can Go Wrong?

• The Risks of Over-Promising in Early-Stage Biologics Development

• The Stability Problem: Why Some Recombinant Antibodies Don’t Make It to Market

• Bengt Thorsson and Johan Rockberg to join Atlas Antibodies’ Board of Directors

• Press release: evitria Celebrates 15 Years with Exclusive Giveaway for Industry Experts

• HEK293 cells for recombinant antibody production

• Engineering bispecific antibodies

• 7 reasons for us to choose Chinese hamster ovary (CHO) cells for recombinant protein production

• evitria and Lonza Sign License Agreement to Provide Fast Access to bYlok® Bispecific Antibodies for Discovery-Stage Transient Expression Research

• Therapeutic antibodies: afucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity (ADCC)

• Transient transfection vs. stable transfection

• Benefits of transient transfection

• How are afucosylated antibodies developed?

• Applications of afucosylated antibodies

• What is antibody discovery?

• Antibody applications – what are antibodies used for?

• IgG Antibodies – 5 facts about Immunoglobulin G

• What is an antibody?

• Glycosylation of proteins

• Afucosylation simply explained

• Antibody characterization: What you need to know

• Antibody engineering: Opportunities & threats

• Antibody production by B cells: 7 facts

• Antibody purification – 3 methods explained

• In vivo antibodies – key facts and considerations

• HEK cells – what’s to know on Human Embryonic Kidney Cells

• Bespoke solutions for lead selection and optimization in cancer antibody research

• Antibody production in bacteria

• Antibody production in animals

• In vitro antibody production

• The Shortcut to Reliable Diagnostic, Control, and Assay Antibodies

• Dr. Stefan Schmidt new CEO of evitria

• The role of CROs in monoclonal antibody production

• Antibody CDMO: Expert Production and Development Services

• What is a CRO?

• Polyclonal, Monoclonal, and Recombinant Antibodies: Differences, Advantages, and Strategic Use

• What are polyclonal antibodies?

• Antibody Production: Types, Technologies & Steps

• Transient transfection – which cell lines are the best option?

• Antibody production in CHO cells: Advantages & Disadvantages

• Schweizer Expertise weltweit gefragt – evitria setzt Wachstumskurs fort

• Purification of His-tagged proteins

• Monoclonal antibodies – all information

• 20,000 antibodies purified – major milestone at evitria

• Types of monoclonal antibodies

• Monoclonal antibody drugs for cancer

• Manufacturers of monoclonal antibodies

• Applications of Monoclonal Antibodies: Diagnostic & Therapeutic Uses

• What are disadvantages of monoclonal antibodies?

• Advantages of monoclonal antibodies in an overview

• Therapeutic monoclonal antibodies – powerful biological drugs

• What is recombinant?

• Mammalian: a definition

• What is a monoclonal antibody?

• Applications of cell culture

All Events

• PEGS Boston 2026

• hubXchange Antibody Therapeutics – Munich

• Antibody Engineering & Therapeutics US

• PEGS Europe 2026

• Festival of Biologics Europe

• hubXchange Antibody Manufacturing – San Francisco

• hubXchange Antibody Therapeutics – Boston

• NextGenBiomed Europe

• Keystone Symposia